Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escalon: HCEC-1 in corneal edema
NCT05309135Phase 1Completed
- Sponsor
- Aurion Biotech
- Start
- Mar 2022
- Primary completion
- Mar 2023
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of neltependocel in corneal edema (3 arms), sponsored by Aurion Biotech. Primary endpoints: Incidence and severity of Treatment Emergent Ocular Adverse Events at 12 months and Incidence and severity of non-ocular Treatment Emergent Adverse Events at 12 months. Started Mar 2022; status: completed.
02
Drugs
neltependocel
03
Conditions
corneal edema
Beyond the preview
Go deeper on NCT05309135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05309135.